Gene Expression Profiling for Allograft Tolerance Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunosuppressive therapies for transplant patients are associated with undesirable side effects and long-term risks, necessitating the identification of individuals who are tolerant to their grafts to reduce or discontinue immunosuppression without risking graft rejection.
Innovation Solution
Methods for determining a graft tolerant phenotype by assessing the expression of specific genes in blood samples, using gene expression profiles to identify individuals who can maintain transplanted organs without immunosuppressive therapy, thereby reducing the need for ongoing immunosuppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunosuppressive therapy is administered to maintain graft viability, then graft rejection is prevented, but undesirable side effects and long-term risks increase
Solution Approach 1:
The patent changes the parameter of immunosuppression intensity from continuous high-dose to reduced or discontinued dosing, based on gene expression profile parameters that indicate graft tolerant phenotype. This allows maintaining graft viability while reducing harmful side effects by adjusting the immunosuppression parameter according to the patient's actual immune status.
Solution Approach 2:
The patent implements a feedback mechanism where gene expression profiles are continuously monitored to determine graft tolerant phenotype, and this information feeds back to adjust immunosuppressive therapy intensity. This closed-loop control system prevents both over-immunosuppression (causing side effects) and under-immunosuppression (causing rejection).
2Object-affected harmful factors
If immunosuppressive therapy is discontinued to reduce side effects, then harmful factors are minimized, but graft rejection risk increases
Solution Approach 1:
The patent performs preliminary identification of graft tolerant phenotype through gene expression profiling before discontinuing immunosuppressive therapy. This advance detection ensures that only patients who have developed true immune tolerance (and will not reject the graft) are selected for therapy reduction, eliminating the risk of rejection that normally accompanies immunosuppression discontinuation.
3Ease of operation
If gene expression profiling is performed to identify graft tolerant individuals, then immunosuppression can be reduced safely, but diagnostic complexity increases
Solution Approach 1:
The patent extracts specific gene expression markers from the complex immune response system that serve as indicators of graft tolerant phenotype. By focusing on these key extracted markers rather than analyzing the entire immune system complexity, the diagnostic method becomes more manageable while still enabling safe immunosuppression reduction decisions.
Data Source
AI summary
Methods are provided for determining whether a subject has a graft tolerant phenotype. In practicing the subject methods, the expression level of one or more gene in a sample from the subject, e.g., a blood sample, is assayed to obtain a gene expression result, where the gene expression result includes a result for a biomarker of graft tolerance. The obtained gene expression result is then employed to determine whether the subject has a graft tolerant phenotype. Also provided are compositions, systems and kits that find use in practicing the subject methods. The methods and compositions find use in a variety of applications, including the determination of an immunosuppressive therapy regimen.